Autres langues Tharimmune, Inc.

Actions

THAR

US4327052001

Temps Différé Nasdaq Autres places de cotation 21:42:58 17/05/2024			Varia. 5j.	Varia. 1 janv.
0,3641 ^USD	-1,14%		-3,19%	-28,47%

09/05	Tharimmune, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
23/04	Tharimmune, Inc. annonce un accord d'option sur des technologies clés pour la création de conjugués médicamenteux à base d'anticorps HER2/HER3 (ADC)	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	24/04
Tharimmune, Inc. Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates	23/04
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate Biotherapeutics	16/04
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024	06/03
Tharimmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate	20/02
Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis	05/02
Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104	29/01
Tharimmune Sees 'Positive' Data With TH104 for Pruritus in Chronic Liver Disease	11/12
Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients	11/12
Sector Update: Health Care Stocks Retreat in Late Afternoon	28/11
Top Midday Decliners	28/11
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell	28/11
Top Premarket Decliners	28/11
Tharimmune Prices $10 Million Public Share Offering	28/11
Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis	27/11
Tharimmune Announces 1-for-25 Reverse Stock Split	20/11
Sector Update: Health Care Stocks Slipping Late Afternoon	17/11
Sector Update: Health Care Stocks Softer Friday Afternoon	17/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Tharimmune, Inc.

Actions

THAR

US4327052001

Autres langues

Filtres